[The cyclic nucleotide system of patients with focal scleroderma].
Studies of the function of cyclic nucleotide system in the lymphocytes of patients with focal scleroderma have revealed that this condition is characterized by growth of the intracellular cAMP/cGMP ratio, correlating with the process duration, severity, and dissemination. A correlation between lymphocyte regulatory function defect and the presence of immunodeficiency syndrome was demonstrated. Sensitivity of lymphocytic cyclic nucleotides in focal scleroderma patients to thymoptin, a thymic agent, was examined. Manifest clinical effect of this drug is based on stabilization of the function of lymphocytic cyclic nucleotides system and, consequently, on normalization of the immunologic parameters. Potentialities and prospects of thymic factors immunotherapy of focal scleroderma patients are discussed.
Suchkova
T N
TN
Sharova
N M
NM
Cheknev
S B
SB
Suchkov
S V
SV
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009712:Nucleotides, Cyclic / Q000097:blood*; D012594:Scleroderma, Localized / Q000097:blood* / Q000188:drug therapy / Q000209:etiology / Q000276:immunology; D013949:Thymus Extracts / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D009712:Nucleotides, Cyclic; D013949:Thymus Extracts
Sistema tsiklicheskikh nukleotidov u bol'nykh ochagovoĭ sklerodermieĭ.